Company Overview
Alphatec Holdings, Inc. operates as a medical technology company dedicated to designing, developing, and advancing technologies for the surgical treatment of spinal disorders across the United States and internationally. The firm manufactures and sells implants, instruments, imaging equipment, and spare parts, with its product portfolio notably including the Alpha I system. This entity functions within the Healthcare sector and specifically targets the Medical Devices industry, where it competes in the specialized niche of spinal care solutions. The company demonstrates a significant market presence with a market capitalization of $1.87B, supported by annual revenue of $764.16M and a workforce of 913 employees. These valuation and revenue figures indicate that the company holds a substantial position within its niche, reflecting a large-scale operation capable of sustaining extensive research and development efforts for spinal disorder technologies while maintaining a global operational footprint.
Financial Health
The company reported revenue of $764.16M for the trailing twelve months, yet recorded a net income of -$143.36M, a disparity that reveals a highly leveraged cost structure where operating expenses and interest costs significantly erode profitability before taxes. Despite the negative net income, the company generated EBITDA of $19.53M, suggesting that core operational cash generation remains positive before the impact of interest, taxes, depreciation, and amortization. Free cash flow stood at $56.15M, which provides a measure of financial flexibility by indicating the cash remaining after capital expenditures, allowing the firm to potentially service debt or fund growth initiatives despite accounting losses. The gross margin is reported at 69.6%, indicating strong pricing power or cost efficiency in manufacturing implants and instruments, while the operating margin of -2.5% and profit margin of -18.8% highlight the severe pressure from overhead costs and interest expenses relative to sales. Total cash on hand of $160.81M is contrasted against total debt of $596.09M, creating a scenario where the balance sheet is heavily leveraged rather than conservative. This leverage is quantified by a debt-to-equity ratio of 1654.48, which signifies that the company relies substantially on borrowed capital to finance its operations and asset base. Liquidity is supported by a current ratio of 2.06, indicating that the company holds sufficient current assets to cover its short-term liabilities more than twice over. However, return metrics such as the return on equity of -630.7% and return on assets of -4.6% reveal that management has been ineffective at generating positive returns on the capital invested by shareholders or the company's total asset base over the measured period.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the negative net income, whereas the forward P/E is 23.15, implying that the market is pricing in future earnings expectations that differ significantly from current accounting results. The price-to-book ratio is 149.04, which indicates a substantial market premium over the company's book value, suggesting that investors are willing to pay significantly more for the equity than the net asset value recorded on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 2.45 and an EV/EBITDA of 119.39, which suggest that the stock is valued highly relative to its sales and earnings power before non-cash charges and interest. Regarding trading range, the 52-week high is $23.29 and the 52-week low is $8.81, placing the stock's valuation in a wide band that reflects significant recent price volatility. The beta value is 1.04, which means the stock's price volatility is slightly higher than the broader market, indicating that the share price tends to move in tandem with general market fluctuations but with added sensitivity. These metrics collectively present a valuation profile that is sensitive to changes in investor sentiment regarding the medical device sector and the company's ability to turn its operational EBITDA into net earnings.
Growth & Income
Revenue growth year-over-year is 20.4%, while earnings growth is N/A due to the current negative net income position, implying that revenue expansion is not yet translating into immediate bottom-line profitability. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which indicates that the firm retains all of its earnings rather than distributing them to shareholders. Consequently, the company reinvests its earnings into growth initiatives such as product development and market expansion rather than paying dividends to provide income to investors. The overall growth and income profile is characterized by robust top-line expansion in the double digits coupled with a complete absence of dividend income, relying entirely on capital appreciation and operational leverage to generate value for equity holders.